455 related articles for article (PubMed ID: 25226850)
1. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.
Rothenberg ME; Wen T; Greenberg A; Alpan O; Enav B; Hirano I; Nadeau K; Kaiser S; Peters T; Perez A; Jones I; Arm JP; Strieter RM; Sabo R; Gunawardena KA
J Allergy Clin Immunol; 2015 Feb; 135(2):500-7. PubMed ID: 25226850
[TBL] [Abstract][Full Text] [Related]
2. Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand?
Ko E; Chehade M
Clin Rev Allergy Immunol; 2018 Oct; 55(2):205-216. PubMed ID: 29372536
[TBL] [Abstract][Full Text] [Related]
3. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Evaluation of Noninvasive Biomarkers for Eosinophilic Esophagitis.
Min SB; Nylund CM; Baker TP; Ally M; Reinhardt B; Chen YJ; Nazareno L; Moawad FJ
J Clin Gastroenterol; 2017 Feb; 51(2):127-135. PubMed ID: 27479142
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation.
Wen T; Dellon ES; Moawad FJ; Furuta GT; Aceves SS; Rothenberg ME
J Allergy Clin Immunol; 2015 Jan; 135(1):187-97. PubMed ID: 25441638
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression.
Molina-Infante J; Rivas MD; Hernandez-Alonso M; Vinagre-Rodríguez G; Mateos-Rodríguez JM; Dueñas-Sadornil C; Perez-Gallardo B; Ferrando-Lamana L; Fernandez-Gonzalez N; Bañares R; Zamorano J
Aliment Pharmacol Ther; 2014 Oct; 40(8):955-65. PubMed ID: 25112708
[TBL] [Abstract][Full Text] [Related]
8. Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease.
Martin LJ; Franciosi JP; Collins MH; Abonia JP; Lee JJ; Hommel KA; Varni JW; Grotjan JT; Eby M; He H; Marsolo K; Putnam PE; Garza JM; Kaul A; Wen T; Rothenberg ME
J Allergy Clin Immunol; 2015 Jun; 135(6):1519-28.e8. PubMed ID: 26051952
[TBL] [Abstract][Full Text] [Related]
9. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis.
Straumann A; Hoesli S; Bussmann Ch; Stuck M; Perkins M; Collins LP; Payton M; Pettipher R; Hunter M; Steiner J; Simon HU
Allergy; 2013 Mar; 68(3):375-85. PubMed ID: 23379537
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis.
Otani IM; Anilkumar AA; Newbury RO; Bhagat M; Beppu LY; Dohil R; Broide DH; Aceves SS
J Allergy Clin Immunol; 2013 Jun; 131(6):1576-82. PubMed ID: 23623266
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis.
van Rhijn BD; Weijenborg PW; Verheij J; van den Bergh Weerman MA; Verseijden C; van den Wijngaard RM; de Jonge WJ; Smout AJ; Bredenoord AJ
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1815-23.e2. PubMed ID: 24657840
[TBL] [Abstract][Full Text] [Related]
12. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.
Spergel JM; Rothenberg ME; Collins MH; Furuta GT; Markowitz JE; Fuchs G; O'Gorman MA; Abonia JP; Young J; Henkel T; Wilkins HJ; Liacouras CA
J Allergy Clin Immunol; 2012 Feb; 129(2):456-63, 463.e1-3. PubMed ID: 22206777
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and gene expression analysis of initial biopsies from patients with eosinophilic esophagitis refractory to therapy.
Siddique AS; Corney DC; Mangray S; Lombardo KA; Chen S; Marwaha AS; Resnick MB; Herzlinger M; Matoso A
Hum Pathol; 2017 Oct; 68():79-86. PubMed ID: 28882697
[TBL] [Abstract][Full Text] [Related]
14. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Hirano I; Collins MH; Assouline-Dayan Y; Evans L; Gupta S; Schoepfer AM; Straumann A; Safroneeva E; Grimm M; Smith H; Tompkins CA; Woo A; Peach R; Frohna P; Gujrathi S; Penenberg DN; Li C; Opiteck GJ; Olson A; Aranda R; Rothenberg ME; Dellon ES;
Gastroenterology; 2019 Feb; 156(3):592-603.e10. PubMed ID: 30395812
[TBL] [Abstract][Full Text] [Related]
15. High Prevalence of Response to Proton-pump Inhibitor Treatment in Children With Esophageal Eosinophilia.
Gutiérrez-Junquera C; Fernández-Fernández S; Cilleruelo ML; Rayo A; Echeverría L; Quevedo S; Bracamonte T; Román E
J Pediatr Gastroenterol Nutr; 2016 May; 62(5):704-10. PubMed ID: 26513622
[TBL] [Abstract][Full Text] [Related]
16. An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results.
Gann PH; Deaton RJ; McMahon N; Collins MH; Dellon ES; Hirano I; Hua SY; Rodriguez C; Harris S
J Allergy Clin Immunol; 2020 Aug; 146(2):367-376.e3. PubMed ID: 32407835
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis.
Butz BK; Wen T; Gleich GJ; Furuta GT; Spergel J; King E; Kramer RE; Collins MH; Stucke E; Mangeot C; Jackson WD; O'Gorman M; Abonia JP; Pentiuk S; Putnam PE; Rothenberg ME
Gastroenterology; 2014 Aug; 147(2):324-33.e5. PubMed ID: 24768678
[TBL] [Abstract][Full Text] [Related]
18. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE.
Clayton F; Fang JC; Gleich GJ; Lucendo AJ; Olalla JM; Vinson LA; Lowichik A; Chen X; Emerson L; Cox K; O'Gorman MA; Peterson KA
Gastroenterology; 2014 Sep; 147(3):602-9. PubMed ID: 24907494
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia.
Park JY; Zhang X; Nguyen N; Souza RF; Spechler SJ; Cheng E
PLoS One; 2014; 9(7):e101391. PubMed ID: 24988451
[TBL] [Abstract][Full Text] [Related]
20. Histological Response to Fluticasone Propionate in Patients With Eosinophilic Esophagitis Is Associated With Improved Functional Esophageal Mucosal Integrity.
van Rhijn BD; Verheij J; van den Bergh Weerman MA; Verseijden C; van den Wijngaard RM; de Jonge WJ; Smout AJ; Bredenoord AJ
Am J Gastroenterol; 2015 Sep; 110(9):1289-97. PubMed ID: 26303134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
